Mary Theoktisto, Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Pkwy, Lakeway, TX 78738 Phone: 512-571-5000 |
News Archive
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
Circumcision performed between ages 3 to 6 years does not adversely affect men's psychosexual function during adulthood, report Turkish researchers.
Ranbaxy Pharmaceuticals, the largest producer of the generic version of Lipitor, has halted production of the drug until it can figure out why glass particles may have ended up in pills that were distributed to the public, the Food and Drug Administration announced Thursday.
› Verified 3 days ago